Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant lymphocytic neoplasm of B-cell or T-cell lineage involving primarily the bone marrow and the peripheral blood. This category includes precursor or acute lymphoblastic leukemias and chronic leukemias.
Biomarker and diagnostic research for lymphoid leukemia has been reported in the published literature.
458 clinical trials registered, 125 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 5 PHASE4, 41 PHASE3, 148 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07218341](https://clinicaltrials.gov/study/NCT07218341) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
PHASE4 |
Eli Lilly and Company |
RECRUITING |
[NCT05131022](https://clinicaltrials.gov/study/NCT05131022) | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | PHASE1 | Nurix Therapeutics, Inc. | RECRUITING |
[NCT07356245](https://clinicaltrials.gov/study/NCT07356245) | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | PHASE2 | Jonathan Brammer | RECRUITING |
[NCT05694312](https://clinicaltrials.gov/study/NCT05694312) | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | PHASE2 | Gruppo Italiano Malattie EMatologiche dell'Adulto | RECRUITING |
[NCT05322850](https://clinicaltrials.gov/study/NCT05322850) | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | PHASE1 | University of Florida | RECRUITING |
500 publications have been identified in PubMed for lymphoid leukemia. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (30%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 157 | 31% |
Laboratory research | 150 | 30% |
Disease patterns and progression | 59 | 12% |
Clinical study results | 43 | 9% |
New treatment approaches | 38 | 8% |
Testing and diagnosis research | 26 | 5% |
Patient case studies | 18 | 4% |
Other research | 9 | 2% |
Iqbal U (2026). [PMID: 41474933](https://pubmed.ncbi.nlm.nih.gov/41474933/). *Expert opinion on investigational drugs*. [Basic Science / Preclinical]
Koch MS (2026). [PMID: 41537229](https://pubmed.ncbi.nlm.nih.gov/41537229/). *Neuro Oncol*. [Basic Science / Preclinical]
Martino EA (2026). [PMID: 41793184](https://pubmed.ncbi.nlm.nih.gov/41793184/). *Clin Transl Med*. [Review / Meta-Analysis]
Michalak K (2026). [PMID: 42089039](https://pubmed.ncbi.nlm.nih.gov/42089039/). *Contemp Oncol (Pozn)*. [Review / Meta-Analysis]
Ryżewska W (2026). [PMID: 42227191](https://pubmed.ncbi.nlm.nih.gov/42227191/). *Expert Rev Hematol*. [Review / Meta-Analysis]
Zhang T (2026). [PMID: 41667896](https://pubmed.ncbi.nlm.nih.gov/41667896/). *Ann Hematol*. [Basic Science / Preclinical]
Nguyen D (2026). [PMID: 41621827](https://pubmed.ncbi.nlm.nih.gov/41621827/). *Cancer Med*. [Epidemiology / Natural History]
Claiborne JP (2026). [PMID: 41691645](https://pubmed.ncbi.nlm.nih.gov/41691645/). *Leuk Lymphoma*. [Clinical Trial Publication]
Niu R (2026). [PMID: 41763134](https://pubmed.ncbi.nlm.nih.gov/41763134/). *Phytomedicine*. [Basic Science / Preclinical]
Graklanov V (2026). [PMID: 41698655](https://pubmed.ncbi.nlm.nih.gov/41698655/). *J Int Med Res*. [Epidemiology / Natural History]